ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Hanmi Science Co., Ltd.

Company Background

Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.

The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.

The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.

Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.

The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.

Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.

In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.

Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.

Business Summary

Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Financial Highlights

Dec 2021 KRWUSD
Revenue950,164.81M829.72M
Gross Profit85,168.86M74.37M
Operating income28,752.86M25.10M
Income before tax19,022.75M16.61M
Net income42,941.99M37.49M
EBITDA34,009.40M29.69M
Diluted EPS638.310.55
Dividends Per Share196.070.17
Total Assets959,696.05M807.31M
Total liabilities269,401.23M226.62M
Total equity690,298.13M580.69M
Operating cash flow13,689.81M11.95M
Currency in KRWCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 652,324.36M 707,995.35M 816,618.82M 857,383.41M 950,164.81M
Gross Profit 28,307.25M 52,344.68M 63,091.98M 75,374.62M 85,168.86M
Operating income 12,704.64M 10,996.88M 16,145.19M 25,151.96M 28,752.86M
Income before tax 33,398.11M 3,661.78M 13,591.04M 22,615.99M 19,022.75M
Net income 30,068.97M 18,019.52M 30,741.64M 22,601.09M 42,941.99M
EBITDA 17,388.56M 15,602.45M 22,519.89M 31,359.89M 34,009.40M
Diluted EPS 450.83 273.44 465.94 335.89 638.31
Dividends Per Share 181.14 184.76 188.46 192.23 196.07
Total Assets 938,783.18M 916,545.95M 910,832.37M 923,219.54M 959,696.05M
Total liabilities 273,630.93M 263,452.03M 265,145.24M 264,485.90M 269,401.23M
Total equity 665,154.16M 653,093.47M 645,685.72M 658,735.54M 690,298.13M
Operating cash flow -33,466.88M 2,701.37M 13,024.00M 13,817.51M 13,689.81M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 577.01M 643.32M 700.24M 726.66M 829.72M
Gross Profit 25.03M 47.56M 54.10M 63.88M 74.37M
Operating income 11.23M 9.99M 13.84M 21.31M 25.10M
Income before tax 29.54M 3.32M 11.65M 19.16M 16.61M
Net income 26.59M 16.37M 26.36M 19.15M 37.49M
EBITDA 15.38M 14.17M 19.31M 26.57M 29.69M
Diluted EPS 0.39 0.24 0.39 0.28 0.55
Dividends Per Share 0.16 0.16 0.16 0.16 0.17
Total Assets 876.91M 821.42M 787.61M 849.87M 807.31M
Total liabilities 255.59M 236.11M 229.27M 243.47M 226.62M
Total equity 621.32M 585.31M 558.33M 606.40M 580.69M
Operating cash flow -29.60M 2.45M 11.16M 11.71M 11.95M

Valuation Measures

Dec 2021
PER84.91
ROA4.56%
ROE6.36%
Operating margin3.02%
Profit margin4.51%

Key executives

  • Chairman & Chief Executive Officer: Young-Sook Song
  • President & Director: Jong-Su Woo
  • Chief Financial Officer: Ki-Ho Song
  • Head-Legal & Compliance Support: Ji-Seon Nam
  • President-Executive Board: Se-Chang Kwon

Shareholders

  • SHIN DONG-GUK (11.9%)
  • SONG YOUNG-SOOK /HANMI/ (11.6%)
  • LIM JONG YOON (7.8%)
  • LIM JU-HYUN (7.1%)
  • LIM JONG-HOON (6.7%)
  • Hanmi Healthcare Co., Ltd. (6.4%)
  • National Pension Service of Korea (5.0%)
  • Gahyun Cultural Foundation (4.9%)
  • Lim Sung-Ki Foundation (3.0%)
  • LIM JIN-HEE (2.1%)

Contact Details

  • Website:http://www.hanmi.co.kr
  • Address: 214 Muha-ro, Paltan-myeon, Hwaseong-si, 18536, South Korea
  • Phone: +82.31.350.5600

Related Companies

  • Hanmi Europe Ltd.
  • Online Pharm. Co. Ltd.
  • Hanmi Japan Pharmaceutical Co. Ltd.

Competitors

  • DAE HWA PHARM Co., Ltd.
Last Updated on 4 Oct, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more